Huvepharma® announces FDA-approval of product to treat swine dysentery, pneumonia

Posted on July 02, 2020

PEACHTREE CITY, GA (June 8, 2020) — Global animal health company Huvepharma® has received FDA-approval for Vetmulin® 12.5% (tiamulin hydrogen fumurate), a liquid concentrate antibiotic that is effective in the treatment of swine dysentery and swine pneumonia. Comprised of the active ingredient tiamulin hydrogen fumarate, Vetmulin 12.5% is a bio-equivalent product to Denagard®.

“Huvepharma is pleased to expand our suite of products and continue to provide effective and economical choices to swine producers as they seek animal health solutions,” says Glen Wilkinson, president of Huvepharma Inc. The company has offered animal health products for cattle, poultry and swine in the U.S. since 2005, and launched several new products within the past year, including Monovet® 90, the first available bio-equivalent monensin. 

Vetmulin 12.5% should be administered according to label directions and should not be used undiluted or with feeds containing polyether ionophores. When administered in drinking water for five consecutive days, tiamulin hydrogen fumarate is effective for the treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae and for treatment of swine pneumonia due to Actinobacillus pleuropneumoniae. If signs of toxicity occur, discontinue use and replace with clean, fresh water. Dosage levels vary depending on which disease is being treated and based on the body weight of the pig. Vetmulin 12.5% is available in both one-liter and five-liter bottles.

Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service.  For more information and complete labeling information, please contact your Huvepharma sales representative and/or Huvepharma’s customer service team at 877-994-4883 or visit www.huvepharma.us.

About Huvepharma

Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarters are located in Peachtree City, GA. 

Huvepharma and Vetmulin® are registered trademarks of Huvepharma EOOD.

Denegard® is a registered trademark of Elanco US Inc.